Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$13.18 - $19.41 $82,546 - $121,564
-6,263 Closed
0 $0
Q1 2022

Aug 25, 2022

BUY
$14.73 - $35.25 $92,253 - $220,770
6,263 New
6,263 $123,000

Others Institutions Holding CVAC

About CureVac N.V.


  • Ticker CVAC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,467,008
  • Market Cap $499M
  • Description
  • CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...
More about CVAC
Track This Portfolio

Track Amalgamated Bank Portfolio

Follow Amalgamated Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.